Vaccine, 2013-01, Vol.31 (3), p.524-532
2013
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
- Ist Teil von
- Vaccine, 2013-01, Vol.31 (3), p.524-532
- Ort / Verlag
- Kidlington: Elsevier Ltd
- Erscheinungsjahr
- 2013
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Highlights ► This Phase 1 trial evaluated the safety and immunogenicity of an RSV (F) nanoparticle vaccine. ► The vaccine was well-tolerated and no related SAEs were observed. ► Both RSV A and B microneutralizating antibodies were increased in vaccinees versus placebo. ► There was a 7- to 19-fold increase in anti-F IgG and a 7- to 24-fold increase in palivizumab-like antibodies. ► The levels of immunity are similar to those seen in other settings with decreased hospitalizations.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0264-410XeISSN: 1873-2518DOI: 10.1016/j.vaccine.2012.11.009Titel-ID: cdi_proquest_miscellaneous_1272734791
- Format
- –
- Schlagworte
- Adjuvants, Immunologic - administration & dosage, Adjuvants, Immunologic - adverse effects, Adolescent, Adult, adults, Allergy and Immunology, Aluminum Compounds - administration & dosage, Aluminum Compounds - adverse effects, Aluminum phosphate, Animals, Anti-F IgG, antibodies, Antibodies, Neutralizing - blood, Antibodies, Viral - blood, Applied microbiology, Biological and medical sciences, Biotechnology, Competitive ELISA, Female, Fundamental and applied biological sciences. Psychology, Fusion protein (F protein), Humans, immune response, immunoglobulin G, Infections, insects, Male, Microbiology, Microneutralization, Middle Aged, Nanoparticle vaccine, Nanoparticles, Nanoparticles - administration & dosage, Nanoparticles - adverse effects, neutralization, Palivizumab, Phosphates - administration & dosage, Phosphates - adverse effects, Placebos - administration & dosage, Placebos - adverse effects, Proteins, Recombinant Fusion Proteins - administration & dosage, Recombinant Fusion Proteins - adverse effects, Recombinant Fusion Proteins - genetics, Recombinant Fusion Proteins - immunology, Respiratory syncytial virus, Respiratory syncytial virus (RSV), Respiratory Syncytial Virus Vaccines - administration & dosage, Respiratory Syncytial Virus Vaccines - adverse effects, Respiratory Syncytial Virus Vaccines - genetics, Respiratory Syncytial Virus Vaccines - immunology, risk reduction, Sf9 Cells, SF9 insect cell, Single-Blind Method, Technology, Pharmaceutical, toxicity, Vaccines, Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects), Vaccines, Synthetic - administration & dosage, Vaccines, Synthetic - adverse effects, Vaccines, Synthetic - genetics, Vaccines, Synthetic - immunology, Vaccines, Virosome - administration & dosage, Vaccines, Virosome - adverse effects, Vaccines, Virosome - genetics, Vaccines, Virosome - immunology, viruses, Young Adult